Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandro Ardizzone

Showing results (131-140 of 157) with videos related to

Pageof 16
Sort By:
Frontiers in Medicine|April 28, 2023
Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel diseaseMarco Vincenzo Lenti, Maria Lia Scribano, Livia Biancone, et al.
Alimentary Pharmacology & Therapeutics|October 25, 2021
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD studyCristina Bezzio, Alessandro Armuzzi, Federica Furfaro, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 23, 2021
Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control populationGiovanni Maconi, Cristina Bosetti, Alberta De Monti, et al.
Pharmacological Research|August 9, 2025
Targeting of the IGFBP3/TMEM219 pathway restores intestinal stem cells capability of healing mucosa in gastrointestinal autoimmune disordersGiovanni Amabile, Francesca D'Addio, Anna Maestroni, et al.
Journal of Gastroenterology and Hepatology|June 23, 2021
Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapySandro Ardizzone, Francesca Ferretti, Maria Camilla Monico, et al.
Journal of Crohn'S & Colitis|March 3, 2016
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD StudyLivia Biancone, Alessandro Armuzzi, Maria Lia Scribano, et al.
JAMA|April 10, 2008
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled TrialsBrian G Feagan, William J Sandborn, Ulrich Mittmann, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 6, 2017
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)Livia Biancone, Vito Annese, Sandro Ardizzone, et al.
Cancers|November 24, 2020
Small Bowel Adenocarcinomas Featuring Special AT-Rich Sequence-Binding Protein 2 (SATB2) Expression and a Colorectal Cancer-Like Immunophenotype: A Potential Diagnostic PitfallGiuseppe Neri, Giovanni Arpa, Camilla Guerini, et al.
Frontiers in Immunology|May 3, 2021
How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study GroupFrancesca Ferretti, Rosanna Cannatelli, Maurizio Benucci, et al.
Pageof 16

Showing results (131-140 of 157) with videos related to

Sort By:
Pageof 16
Frontiers in Medicine|April 28, 2023
Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel diseaseMarco Vincenzo Lenti, Maria Lia Scribano, Livia Biancone, et al.
Alimentary Pharmacology & Therapeutics|October 25, 2021
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD studyCristina Bezzio, Alessandro Armuzzi, Federica Furfaro, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 23, 2021
Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control populationGiovanni Maconi, Cristina Bosetti, Alberta De Monti, et al.
Pharmacological Research|August 9, 2025
Targeting of the IGFBP3/TMEM219 pathway restores intestinal stem cells capability of healing mucosa in gastrointestinal autoimmune disordersGiovanni Amabile, Francesca D'Addio, Anna Maestroni, et al.
Journal of Gastroenterology and Hepatology|June 23, 2021
Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapySandro Ardizzone, Francesca Ferretti, Maria Camilla Monico, et al.
Journal of Crohn'S & Colitis|March 3, 2016
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD StudyLivia Biancone, Alessandro Armuzzi, Maria Lia Scribano, et al.
JAMA|April 10, 2008
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled TrialsBrian G Feagan, William J Sandborn, Ulrich Mittmann, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 6, 2017
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)Livia Biancone, Vito Annese, Sandro Ardizzone, et al.
Cancers|November 24, 2020
Small Bowel Adenocarcinomas Featuring Special AT-Rich Sequence-Binding Protein 2 (SATB2) Expression and a Colorectal Cancer-Like Immunophenotype: A Potential Diagnostic PitfallGiuseppe Neri, Giovanni Arpa, Camilla Guerini, et al.
Frontiers in Immunology|May 3, 2021
How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study GroupFrancesca Ferretti, Rosanna Cannatelli, Maurizio Benucci, et al.
Pageof 16